• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

803.17 +19.52 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 974,848
Open 788.92
Bid (Size) 798.50 (40)
Ask (Size) 805.00 (40)
Prev. Close 783.65
Today's Range 785.00 - 806.18
52wk Range 476.49 - 821.11
Shares Outstanding 91,779,465
Dividend Yield 0.44%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
February 12, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only... 
Via StockStory
Topics Stocks
News headline image
Regeneron Announces Investor Conference Presentations
February 11, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+3.5%
+3.5%
1 Month
+8.3%
+8.3%
3 Month
+14.0%
+14.0%
6 Month
+39.9%
+39.9%
1 Year
+19.2%
+19.2%

More News

Read More
News headline image
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
February 10, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? ↗
February 02, 2026
Via Stocktwits
Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition ↗
January 30, 2026
Via Chartmill
Topics Earnings
News headline image
The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data
February 06, 2026
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Regeneron (REGN) Q1 2025 Earnings Call Transcript ↗
February 05, 2026
Via The Motley Fool
Topics Earnings Supply Chain
News headline image
Regeneron (REGN) Q2 2025 Earnings Call Transcript ↗
February 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Regeneron (REGN) Q4 2024 Earnings Call Transcript ↗
February 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Regeneron (REGN) Q3 2024 Earnings Call Transcript ↗
February 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 02, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business ↗
January 30, 2026
Via The Motley Fool
News headline image
Regeneron (REGN) Q4 2025 Earnings Call Transcript ↗
January 30, 2026
Via The Motley Fool
Topics Earnings
These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
January 30, 2026
Via Chartmill
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
January 30, 2026
Via Stocktwits
News headline image
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025
January 30, 2026
Via StockStory
News headline image
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
January 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow
January 28, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks Poised for a Comeback in 2026 ↗
January 22, 2026
Via The Motley Fool
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
January 20, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
January 19, 2026
Via MarketBeat
Topics ETFs
News headline image
3 Profitable Stocks We Think Twice About
January 18, 2026
Via StockStory
News headline image
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds
January 12, 2026
Via StockStory
Topics Economy Energy
News headline image
Regeneron Just Moved From Underperform To Buy - Here's Why ↗
January 07, 2026
Via Benzinga
These S&P500 stocks are moving in today's session ↗
January 07, 2026
Via Chartmill

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 803.17
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 02/13/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 73.71B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 74B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap